NEURONETICS, INC.

Consensus Neuronetics, Inc.

Equities

STIM

US64131A1051

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-13 pm EDT			5-day change	1st Jan Change
3.790 ^USD	-0.52%		+1.88%	+135.40%

Jun. 10	Neuronetics Announces Clinical Presence At The 2025 Clinical TMS Society Annual Meeting And Progress In Greenbrook's Personalized Care Trial Program	RE
Jun. 02	Neuronetics Set To Join Russell 2000® And Russell 3000® Indexes	RE

Evolution of the Average Target: Neuronetics, Inc.

Evolution of the Target Price: Neuronetics, Inc.

Changes in Analyst Recommendations: Neuronetics, Inc.

4e3d0714.Z64byXPjOVD8myGeyy5sn2DKrylddHd_fg2hxyyAmUE.MsFjmUGbDCqV6UD0pBwI0i-F9noHP0ZOEleUs3_u6hEK5FqmIotsJJvhTg~c064214033a6822961048d73b7963616

Analysts' recommendations: Neuronetics, Inc.

William Blair Downgrades Neuronetics to Market Perform From Outperform	24-08-13	MT
William Blair Upgrades Neuronetics to Outperform From Market Perform	24-05-14	MT
Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating	23-03-08	MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating	22-01-03	MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating	21-10-14	MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform	21-10-13	MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy	21-10-13	MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform	21-01-22	MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating	21-01-21	MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating	20-12-07	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	NEURONETICS, INC.					+80.3%
	INTUITIVE SURGICAL, INC.					+12.36%
	THERMO FISHER SCIENTIFIC INC.					+38.82%
	BOSTON SCIENTIFIC CORPORATION					+17.33%
	DANAHER CORPORATION					+23.16%
	SIEMENS HEALTHINEERS AG					+31.87%
	EDWARDS LIFESCIENCES CORPORATION					+7.61%
	SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.					+29.25%
	RESMED, INC.					+6.08%
	AGILENT TECHNOLOGIES, INC.					+16.86%
	Average					+26.36%
	Weighted average by Cap.					+21.72%

See all sector consensus

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

OUTPERFORM

Number of Analysts

4

Last Close Price

3.790USD

Average target price

6.833USD

Spread / Average Target

+80.30%

High Price Target

8.000USD

Spread / Highest target

+111.08%

Low Price Target

5.500USD

Spread / Lowest Target

+45.12%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

William Blair & Co.
Canaccord Genuity
Piper Sandler
JMP Securities
BTIG

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Stock Market
Equities
STIM Stock
Consensus Neuronetics, Inc.